Repligen’s Strong Q1 Performance and Strategic Acquisition Justify Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on RGEN stock, giving a Buy rating on April 25.

Matt Larew has given his Buy rating due to a combination of factors including Repligen’s impressive first-quarter performance, which exceeded expectations in several key financial metrics. The company reported revenue of $169.1 million, surpassing the anticipated $165.6 million, and adjusted EBITDA of $32.7 million, which was significantly higher than the forecasted $26.8 million. Additionally, the adjusted EPS of $0.39 beat both the estimate and consensus.
Despite mixed guidance adjustments, Repligen’s organic growth remains robust, with non-COVID growth projected between 11.5% and 15.5%, an increase from previous estimates. The acquisition of 908 Devices’ bioprocessing portfolio is expected to contribute positively to revenue, although it may slightly impact operating margins. The company’s strong performance in biopharma and consumables, with over 20% growth in revenue and double-digit growth across all franchises, further supports the Buy rating, highlighting Repligen’s potential for continued success.

According to TipRanks, Larew is an analyst with an average return of -8.0% and a 38.46% success rate. Larew covers the Healthcare sector, focusing on stocks such as Repligen, 908 Devices, and Option Care Health.